Abstract
Using nucleotide sequences of SARS-CoV-2 strains collected in Japan, the relative instantaneous reproduction numbers of the R.1, Alpha, and Delta variants with respect to other strains circulation in Japan were estimated at 1.256, 1.449, and 1.776, respectively. The numbers can range 1.198–1.335 for R.1, 1.342–1.596 for Alpha, and 1.557–2.00 for Delta depending on the assumed serial interval distributions. The frequency of the Delta is expected to take over the Alpha in Japan around July 12, 2021.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Japan Agency for Medical Research and Development (grant numbers JP20fk0108535). K.I. received funding JSPS KAKENHI (21H03490). P.C. was supported by the World-leading Innovative and Smart Education Program (1801) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. H.N. received funding from Health and Labor Sciences Research Grants (20CA2024 and 20HA2007); the Japan Agency for Medical Research and Development (JP20fk0108140); JSPS KAKENHI (21H03198) and the Japan Science and Technology Agency (JST) SICORP (e-ASIA) program (JPMJSC20U3). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw data used for the analysis were provided as Supplementary Table 1.
